CN107998335B - 用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂 - Google Patents
用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂 Download PDFInfo
- Publication number
- CN107998335B CN107998335B CN201711375826.6A CN201711375826A CN107998335B CN 107998335 B CN107998335 B CN 107998335B CN 201711375826 A CN201711375826 A CN 201711375826A CN 107998335 B CN107998335 B CN 107998335B
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- liver injury
- chemical liver
- auxiliary protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims abstract description 60
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 58
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 18
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 18
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 18
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 17
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 17
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 17
- 235000013976 turmeric Nutrition 0.000 claims abstract description 17
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 16
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 9
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 9
- 241000736199 Paeonia Species 0.000 claims abstract description 8
- 241001106477 Paeoniaceae Species 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 19
- 230000002829 reductive effect Effects 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 235000014375 Curcuma Nutrition 0.000 claims description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 210000004185 liver Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- 201000007930 alcohol dependence Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000407170 Curcuma Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940124976 antitubercular drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000013245 carbon tetrachloride model Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229940049413 rifampicin and isoniazid Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及保健品技术领域,具体公开一种用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂。所述用于化学性肝损伤有辅助保护功能的组合物,按质量份数计,包括如下组分:葛根:2‑5份,姜黄:1‑3份,枳椇子:2‑5份,牡丹皮:1‑4份,赤芍:1‑3份,青皮:1‑3份。本发明以葛根和姜黄采用共醇提取,枳椇子、牡丹皮、赤芍和青皮采用共水提取,得到所述组合物。同时所述用于化学性肝损伤有辅助保护功能的组合物与赋形剂可以得到中药制剂,在保健品技术领域有广泛应用。
Description
技术领域
本发明涉及保健品技术领域,尤其涉及一种用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂。
背景技术
化学性肝损伤是指由化学性肝毒性物质所造成的肝脏的损伤。造成化学性肝损伤的原因主要有三方面:一是食物中的有害物质,如霉变食物产生的毒素,还有食品中的化学添加剂如防止食品腐败的防腐剂,为食品着色的着色剂等,以及大众喜爱的咸菜、酸菜中含有的亚硝酸钠;二是:酒中所含有的酒精;三是:药物中的有害成分,如抗生素中的青霉素、先锋霉素等,一线抗结核药中的利福平、异烟肼等;化疗药如环磷酰胺、甲氨蝶呤等,它们都要通过肝脏来解毒。有毒物质作用于肝脏,首先是脂质过氧化反应,造成细胞的结构与功能的改变;然后是干扰脂蛋白的合成与转运,造成肝的脂肪变性,形成脂肪肝;接着肝细胞膜和微绒毛受损,引起胆汁酸排泄障碍,造成胆汁郁积反应;最后是肝细胞凋亡或坏死,进而向肝纤维化、肝硬化及肝肿瘤等严重危害人类健康的方向发展。
中医文献中无化学性肝损伤的病名,根据其临床表现可归属于中医学中的“劳倦”、“胁痛”、“黄疸”、“积聚”等范畴。肝主疏泄,能调节气机的运行,抑郁恼怒等情志刺激以及药毒、酒毒的外侵都可造成肝气郁结,也为各种疾病的发生奠定了基础。同时,早期药毒、酒毒等损伤脾胃,脾失健运,津液代谢、疏布失调,湿邪内生,久而化热,湿热蕴结,进一步加重气滞,肝胆失于疏泄,可有胸胁胀痛或窜痛或善太息,失眠多梦等症状;气行则血行,气滞则血亦滞,继而可发展为胁肋刺痛,舌质青紫,妇女可见月经不调、闭经、痛经等症状;气血瘀滞,日久不散,则可形成积聚痞块诸证。因此,开发一种对化学性肝损伤有保护辅助保护作用的产品具有很大的市场前景。
发明内容
针对现有化学性肝损伤日渐严重等问题,本发明提供一种用于化学性肝损伤辅助保护的组合物。
进一步地,本发明还提供一种用于化学性肝损伤辅助保护的组合物的制备方法。
进一步地,本发明还提供一种用于化学性肝损伤辅助保护的中药制剂。
为达到上述发明目的,本发明实施例采用了如下的技术方案:
一种用于化学性肝损伤辅助保护的组合物,所述组合物按质量份数计,包括如下组分:葛根:2-5份,姜黄:1-3份,枳椇子:2-5份,牡丹皮:1-4份,赤芍:1-3份,青皮:1-3份。
相对于现有技术,本发明提供的针对化学性肝损伤属于湿热蕴结、气滞血瘀的人群,组合物中的枳椇子甘、酸,平。归脾经。《本草拾遗》言其“止渴除烦,去膈上热,润五脏,利大小便。”明代的《证治准绳》中记载“解酒毒无如枝矩子之妙”。《本草纲目》中记载:“止呕逆”。《滇南本草》谓其“能解酒毒”“健胃养脾”,《中华本草》载:“解酒毒。”有利水消肿,解酒毒之功。葛根甘、辛,凉。归脾、胃经。《本经》言其“主消渴,身太热,呕吐,诸痹,起阴气,解诸毒。”《药性论》谓其:“治天行上气,呕逆,开胃下食,主解酒毒,止烦渴。”《本草拾遗》谓其“生者破血……解酒毒,身热赤,酒黄,小便赤涩。”有升发清阳、生津止渴、解酒毒、通经活络之功。与枳椇子相伍既能消除湿热、药毒、酒毒以治本,又能升发脾胃清阳、化瘀通络以治标,相得益彰,二者用作君药。
姜黄辛、苦,温。归肝、脾经。《新修本草》载其:“主心腹结积,疰忤,下气,破血。”《日华子本草》言其“治癥瘕血块,痈肿,通月经,治跌仆瘀血,消肿毒,止暴风痛,冷气,下食。”有活血行气,通经止痛之功。赤芍苦、微寒。归肝经。《神农本草经》言其:“主邪气腹痛,除血痹,破坚积,寒热疝瘕,止痛,利小便。”《本草求真》记载:“赤芍则止有散邪行血之意……赤芍则能于血中活滞。故凡腹痛坚积,血瘕疝痹,经闭目赤,因于积热而成者,用此则能凉血逐瘀。”具有清热凉血,散瘀止痛的功能。牡丹皮苦、甘,微寒。归心、肝、肾经。《神农本草经》称其:“除坚癥瘀血留舍肠间,安五脏。”具有清热凉血,活血祛瘀的功能。三者共用,可活血行气,祛瘀清肝,同用作臣药。
青皮苦、辛,温。归肝、胆、胃经。辛散温通,苦泄下行而奏疏肝理气、散结止痛之功。尤宜于治肝郁气滞之胸胁胀痛。《本草汇言》云:“青橘皮,破滞气,削坚积之药也……此剂苦能泄,辛能散引,能辟邪消瘴,运行水谷,诚专功也。”青皮气味峻烈,苦泄力大,辛散温通力强,能破气散结、疏肝理气。可畅行肝经气滞,解酒毒、散癥积。用作佐使药。
诸品同用,针对化学性肝损伤属湿热蕴积、气滞血瘀的人群,可发挥清利湿热、疏肝理气、活血化瘀之功。且没有配伍禁忌,安全而有效,可发挥良好的保肝作用。
进一步地,本发明还提供所述用于化学性肝损伤辅助保护的组合物的制备方法。该制备方法,至少包括以下步骤:
步骤1、按照上述的原料配比称取各组分;
步骤2、将葛根和姜黄采用共醇提取,得到醇提液,减压浓缩至相对密度为1.08-1.12,粉碎得到干膏粉A;
步骤3、将枳椇子、牡丹皮、赤芍和青皮采用共水提取,得到水提液,减压浓缩至相对密度为1.08-1.12,粉碎得到干膏粉B;
步骤4、将所述干膏粉A和干膏粉B混合,得到用于化学性肝损伤有辅助保护功能的组合物。
相对于现有技术,本发明提供的用于化学性肝损伤有辅助保护功能的组合物的制备方法,葛根和姜黄采用共醇提取,出膏率20-21%,枳椇子、牡丹皮、赤芍和青皮采用共水提取,出膏率22-23%。
相应地,本发明提供了该用于化学性肝损伤辅助保护的中药制剂,所述中药制剂中含有所述的用于化学性肝损伤辅助保护的组合物或含有所述方法制备的用于化学性肝损伤辅助保护的组合物。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
本发明实施例提供一种用于化学性肝损伤有辅助保护功能的组合物,所述组合物按质量份数计,包括如下组分:葛根:2-5份,姜黄:1-3份,枳椇子:2-5份,牡丹皮:1-4份,赤芍:1-3份,青皮:1-3份。
优选地,所述组合物按质量份数计,包括如下组分:葛根:3份,姜黄:2份,枳椇子:3份,牡丹皮:2份,赤芍:2份,青皮:2份。
本发明以枳椇子和葛根为君药,姜黄、牡丹皮、赤芍为臣药,青皮作佐使药,共同协同作用,达到对化学性肝损伤有辅助保护功能。
本发明在提供该由于化学性肝损伤有辅助保护功能组合物的前提下,还进一步提供了该用于化学性肝损伤有辅助保护功能组合物的制备方法。
在任一实施例中,该制备方法至少包括以下步骤:
步骤1、按照上述的原料配比称取各组分;
步骤2、将葛根和姜黄采用共醇提取,得到醇提液,减压浓缩至相对密度为1.08-1.12,粉碎得到干膏粉A;
步骤3、将枳椇子、牡丹皮、赤芍和青皮采用共水提取,得到水提液,减压浓缩至相对密度为1.08-1.12,粉碎得到干膏粉B;
步骤4、将所述干膏粉A和干膏粉B混合,得到对化学性肝损伤有辅助保护功能的组合物。
优选地,所述步骤2中共醇提取的步骤为:将葛根和姜黄粉碎,以8-10倍量的70%乙醇浸泡,提取2-3次,每次0.5-2h,合并提取液,得到醇提液。
优选地,所述步骤2中减压浓缩的真空度为-0.06Mpa~-0.08Mpa,温度为60~65℃。
优选地,所述步骤3中水提液的步骤为:将枳椇子、牡丹皮、赤芍和青皮混合,以8-10倍量的水浸泡,煎煮2-3次,每次0.5-2h,合并提取液,得到水提液。
优选地,所述步骤3中减压浓缩的真空度为-0.06Mpa~-0.08Mpa,温度为55~60℃。
本发明以葛根和姜黄采用共醇提取,枳椇子、牡丹皮、赤芍和青皮采用共水提取,提取液含量高,方法简单,过程容易控制。
一种用于化学性肝损伤辅助保护的中药制剂,所述中药制剂中含有所述的用于化学性肝损伤辅助保护的组合物或含有所述方法制备的用于化学性肝损伤辅助保护的组合物。
优选地,所述用于化学性肝损伤辅助保护的中药制剂,还包括医药上可接受的赋形剂,且所述中药制剂由用于化学性肝损伤辅助保护的组合物和所述赋形剂制成。
所述用于化学性肝损伤有辅助保护功能的组合物在制备对化学性肝损伤有辅助保护作用的保健品中的应用。
为了更好的说明本发明实施例提供的,下面通过实施例做进一步的举例说明。
实施例1
本实施例提供一种用于化学性肝损伤有辅助保护功能的组合物,所述组合物按质量份数计,包括如下组分:葛根:750份,姜黄:500份,枳椇子:750份,牡丹皮:500份,赤芍:500份,青皮:500份。
用于化学性肝损伤有辅助保护功能的中药制剂还包括赋形剂,其中微晶纤维素:536份,交联聚维酮:70份,硬脂酸镁:14份,薄膜包衣预混剂:35份。
上述用于化学性肝损伤有辅助保护功能的中药制剂的制备方法,所述制备方法包括以下步骤:
步骤1、按照上述的原料配比称取各组分;
步骤2、将葛根和姜黄采用共醇提取,得到醇提液,减压浓缩、粉碎得到干膏粉A;将葛根和姜黄粉碎,第一次以10倍量的70%乙醇浸泡2h,提取2h,第二次以8倍量的70%乙醇浸泡2h,提取2h,合并提取液,得到醇提液,然后将醇提液在温度为60~65℃,真空度为-0.06Mpa~-0.08Mpa条件下减压浓缩,至相对密度为1.08-1.12,出膏率为21%,最后粉碎,过80目筛,得到干膏粉A;
步骤3、将枳椇子、牡丹皮、赤芍和青皮采用共水提取,第一次以10倍量的水浸泡2h,煎煮2h,第二次以8倍量的水浸泡2h,煎煮2h,合并提取液,得到水提液,然后将水提液在温度为55~60℃,真空度为-0.06Mpa~-0.08Mpa的条件下减压浓缩,至相对密度为0.108-1.12,出膏率为23%,最后粉碎,过80目筛,得到干膏粉B;
步骤4、将赋形剂微晶纤维素和交聚维酮分别粉碎过80目筛,与干膏粉A和干膏粉B混合均匀,采用95%乙醇制粒,用量为配方量的48%,20目筛制粒,在55~60℃下干燥至水分≤5%,20目筛整粒;
步骤5、将赋形剂硬脂酸镁粉碎过80目筛与步骤4得到的颗粒混合均匀,得到总混颗粒,压片0.7g/片,得到素片;
步骤6、将赋形剂薄膜包衣预混剂加70%乙醇配置成10%的溶液,与步骤5中的素片得到包衣片,检验得到用于化学性肝损伤有辅助保护功能的中药制剂。
上述步骤2和步骤3中,干膏粉A中含有0.63g葛根,0.42g姜黄,干膏粉B中含有0.69g枳椇子,0.46g牡丹皮,0.46g赤芍,0.46g青皮。
上述步骤中从步骤2中的减压浓缩到步骤6中得到包衣片均在10万级洁净区内进行反应。
用法用量:0.7g/片,每日2次,每次4片。
实施例2
提供实施例1制备的用于化学性肝损伤有辅助保护功能的中药制剂的药效实验。
将50只ICR小鼠随机分成5组,每组10只,分别为正常对照组,肝损伤模型对照组,和实验组。实验组分别为:本发明实施例1药物低剂量组,本发明实施例1药物中剂量组,本发明实施例1高剂量组。
正常对照组:给予蒸馏水,按照0.2mL/20g体重给小白鼠灌胃。
模型对照组:给予蒸馏水,按照0.2mL/20g体重给小白鼠灌胃。
药物低剂量组:将实施例1制备的中药制剂,按照小白鼠每1Kg体重,给予中药制剂0.8g的标准,将中药制剂配置成水溶液,按照0.2mL/20g体重给小白鼠灌胃。
药物中剂量组:将实施例1制备的中药制剂,按照小白鼠每1Kg体重,给予中药制剂1.6g的标准,将中药制剂配置成水溶液,按照0.2mL/20g体重给小白鼠灌胃。
药物高剂量组:将实施例1制备的中药制剂,按照小白鼠每1Kg体重,给予中药制剂2.4g的标准,将中药制剂配置成水溶液,按照0.2mL/20g体重给小白鼠灌胃。
连续30天后,各组小鼠隔夜进食16小时,模型对照组及各剂量组一次灌胃0.5%四氯化碳10mL/Kg体重,正常对照组给植物油,各实验组继续给予药物至实验结束(与四氯化碳灌胃间隔4小时以上)。给予四氯化碳24小时候处死动物,取血分离血清,测定ALT、AST。
造模前,各组小鼠可正常饮食,皮毛光泽,活动良好,反应敏捷,体重逐期增长。四氯化碳造模后,除正常对照组外小鼠明显活动减弱,皮毛暗淡,并发现模型组小鼠有活动简慢、不太不稳现象。
正常对照组、模型组及各剂量组的实验结果见表1。
表1血清中ALT、AST的含量
与正常对照组比较:+p<0.05,++p<0.01。
与模型对照组比较:*P<0.05,**P<0.05。
由表1可知,正常对照组的ALT、AST含量明显低于四氯化碳模型对照组,存在明显差异,说明模型成立;本发明的实验组,即高、中、低三种剂量组的ALT、AST含量明显降低,与模型对照组比较,均存在显著差异(P<0.05)。说明本发明含有用于化学性肝损伤辅助保护的组合物的中药制剂,对化学性肝损伤具有辅助保护的作用。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换或改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种用于化学性肝损伤辅助保护的组合物,其特征在于:所述组合物按质量份数计,由如下组分组成:葛根:2-5份,姜黄:1-3份,枳椇子:2-5份,牡丹皮:1-4份,赤芍:1-3份,青皮:1-3份。
2.如权利要求1所述的用于化学性肝损伤辅助保护的组合物,其特征在于:所述组合物按质量份数计,由如下组分组成:葛根:3份,姜黄:2份,枳椇子:3份,牡丹皮:2份,赤芍:2份,青皮:2份。
3.一种用于化学性肝损伤辅助保护的组合物的制备方法,其特征在于:至少包括以下步骤:
步骤1、按照权利要求1-2任一项所述的原料配比称取各组分;
步骤2、将葛根和姜黄采用共醇提取,得到醇提液,减压浓缩至相对密度为1.08-1.12,粉碎得到干膏粉A;
步骤3、将枳椇子、牡丹皮、赤芍和青皮采用共水提取,得到水提液,减压浓缩至相对密度为1.08-1.12,粉碎得到干膏粉B;
步骤4、将所述干膏粉A和干膏粉B混合,得到用于化学性肝损伤有辅助保护功能的组合物。
4.如权利要求3所述的用于化学性肝损伤辅助保护的组合物的制备方法,其特征在于:所述步骤2中共醇提取的步骤为:将葛根和姜黄粉碎,以8-10倍量的70%乙醇浸泡,提取2-3次,每次0.5-2h,合并提取液,得到醇提液。
5.如权利要求3-4任一项所述的用于化学性肝损伤辅助保护的组合物的制备方法,其特征在于:所述步骤2中减压浓缩的真空度为-0.06Mpa~-0.08Mpa,温度为60~65℃。
6.如权利要求3所述的用于化学性肝损伤辅助保护的组合物的制备方法,其特征在于:所述步骤3中水提液的步骤为:将枳椇子、牡丹皮、赤芍和青皮混合,以8-10倍量的水浸泡,煎煮2-3次,每次0.5-2h,合并提取液,得到水提液。
7.如权利要求3或6任一项所述的用于化学性肝损伤辅助保护的组合物的制备方法,其特征在于:所述步骤3中减压浓缩的真空度为-0.06Mpa~-0.08Mpa,温度为55~60℃。
8.一种用于化学性肝损伤辅助保护的中药制剂,其特征在于:所述中药制剂中含有权利要求1或2所述的用于化学性肝损伤辅助保护的组合物或含有权利要求3-7任一项所述方法制备的用于化学性肝损伤辅助保护的组合物。
9.如权利要求8所述的用于化学性肝损伤辅助保护的中药制剂,其特征在于,还包括医药上可接受的赋形剂,且所述中药制剂由用于化学性肝损伤辅助保护的组合物和所述赋形剂制成。
10.如权利要求1-2任一项所述的组合物在制备对化学性肝损伤有辅助保护作用的保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711375826.6A CN107998335B (zh) | 2017-12-19 | 2017-12-19 | 用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711375826.6A CN107998335B (zh) | 2017-12-19 | 2017-12-19 | 用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107998335A CN107998335A (zh) | 2018-05-08 |
CN107998335B true CN107998335B (zh) | 2020-12-18 |
Family
ID=62059980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711375826.6A Active CN107998335B (zh) | 2017-12-19 | 2017-12-19 | 用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107998335B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104383447A (zh) * | 2014-12-01 | 2015-03-04 | 天津中新药业集团股份有限公司达仁堂制药厂 | 一种中药药物组合物及其制备方法与应用 |
-
2017
- 2017-12-19 CN CN201711375826.6A patent/CN107998335B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104383447A (zh) * | 2014-12-01 | 2015-03-04 | 天津中新药业集团股份有限公司达仁堂制药厂 | 一种中药药物组合物及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
中西医结合治疗药物性肝损伤临床研究;付月箫等;《中国中医急症》;20060831;第15卷(第08期);850-851 * |
保肝饮对于CCl_4所致肝损伤大鼠模型生化指标及肝组织病理切片的影响;冯志鹏等;《武警医学》;20050630;第16卷(第06期);429-432 * |
化肝汤1号治疗酒精性肝纤维化症状及肝功能改变;郝彦开等;《医学综述》;20120630;第18卷(第11期);1753-1755 * |
Also Published As
Publication number | Publication date |
---|---|
CN107998335A (zh) | 2018-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103533948A (zh) | 神经疾病的治疗及记忆力减退改善用生药组合物 | |
CN104436018A (zh) | 治疗肿瘤的药物及其制备方法 | |
CN101032593A (zh) | 一种治疗痤疮的中药制剂 | |
CN102078569A (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
CN107998335B (zh) | 用于化学性肝损伤辅助保护的组合物、其制备方法及中药制剂 | |
CN104161952A (zh) | 治疗甲状腺肿瘤的中药组合物及其制备方法 | |
CN115006494B (zh) | 一种显脉旋覆花复合解酒组合物、解酒护肝制剂及其应用 | |
CN103751547B (zh) | 一种降血脂的中药组合物及其制备方法 | |
CN103652450B (zh) | 一种猪饲料及其制备方法 | |
CN102357151B (zh) | 一种延缓衰老的中药组合物及其制备工艺 | |
CN104383050B (zh) | 一种内外结合治疗风湿性关节炎的药物及制备方法 | |
CN103446387B (zh) | 一种治疗甲亢的中药组合物及制备方法 | |
CN113230324A (zh) | 一种治疗肿瘤靶向药物相关皮炎的中药组合物及其应用 | |
CN109349640A (zh) | 一种改善化学性肝损伤的保健胶囊 | |
CN114848764B (zh) | 一种防治肝损伤的中药复方组合物及其制备方法和应用 | |
CN115154568B (zh) | 一种治疗甲状腺结节的中药组合物及其制备方法和应用 | |
LU504224B1 (en) | Traditional chinese medicine composition for preventing and treating fatty liver and preparation method thereof | |
CN113384667B (zh) | 一种防治肝损伤和/或肝癌的药物组合物及其制备方法和用途 | |
CN103800449B (zh) | 一种治疗阴虚热盛证2型糖尿病的中药组合物 | |
CN106074960A (zh) | 一种治疗乳腺癌及乳腺增生的中药组合物及其制备方法 | |
CN104337889B (zh) | 一种含蚯蚓的治疗痛风的中药组合物 | |
CN105435202A (zh) | 一种治疗胃炎的药物制剂及其用途 | |
CN104491557A (zh) | 一种治疗邪阻胃肠型有机磷农药中毒的药物及其制备方法 | |
CN115919939A (zh) | 一种治疗乳腺增生的中药组合物及其制备方法与应用 | |
CN113663024A (zh) | 一种治疗病毒性心肌炎的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200527 Address after: No.012, Jiazhuang administrative village, Jiazhuang Town, Mudan District, Heze City, Shandong Province Applicant after: Lan Xiang Address before: 101300, No. two, 1 road, Shunyi Park, Zhongguancun science and Technology Park, Beijing, Shunyi District Applicant before: ZHONGTAI YIJIA HEALTH TECHNOLOGY (BEIJING) Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |